Family Site

The contents provided by this page is intended for patients prescribed with Remsima® subcutaneous(SC). If you are an Australian Healthcare Professional , please click the relevant button.

This site is only for residents of Australia who have been prescribed Remsima® SC. If you have not been prescribed Remsima® nor a resident of Australia, click “leave”.

Enter Leave

The Infliximab dual formulation provides
tailored treatment based on your needs.1

You can also report side effects directly to Therapeutic Goods Administration (TGA) in accordance with their requirements.

If you experience any side effects when taking Remsima® or any other medicine, talk to your doctor, pharmacist or nurse.
This includes possible side effects not listed in the packaging leaflet.
You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects, you can help provide more information on the safety of this medicine.

References

1.  Jin, Jing-Fen et al. “The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.” Patient preference and adherence vol. 9 923-42. 2 Jul. 2015, doi:10.2147/PPA.S87271

Abbreviations

SC, subcutaneous; FAQ, frequently asked questions